Urinary pH: its regulation and relevance in urolithiasis metaphylaxis

Urolithiasis is a common multifactorial disease characterized by a high recurrence rate. This review is devoted to the urine pH as one of the main factors determining its lithogenic properties. It affects the excretion of lithogenic substances and stone formation inhibitors, the solubility, and the crystallization of substances involved in stone formation. The urine pH significantly affects the solubility of uric acid in urine, which decreases at a pH < 5.5. This explains the high incidence of uric acid concretions in patients with metabolic syndrome. Their insulin resistance leads to a decrease in the excretion of ammonium ions in the proximal tubules, leading to persistent urine acidification. The activity of many transport processes involved in the processing of calcium, citrates and phosphates is sensitive to changes in systemic or local pH. The data on the effect of urine pH on the solubility of calcium oxalate remain contradictory. At the same time, there is no doubt about the determining role of urine pH in the excretion of citrate, the most important stone formation inhibitor. The alkaline urine pH promotes the formation of concretions containing calcium phosphates. In conditions of constantly elevated urine pH in patients with persistent urease-producing urinary tract infection, a rapid growth of "infectious" concretions occurs. The review summarizes information on the causes of the decrease and increase in the urine pH, as well as the possibilities of medicinal and non-medicinal methods of modifying the urine pH during the prevention of stone formation recurrence.

1. Wein AJ, Kavoussi LR, Partin AW, Peters AC. Campbell-Walsh Urology: 4-Volume Set. 11th Edition. Philadelphia: Elsevier; 2015. ISBN-10: 1455775673.

2. Sorokin I, Mamoulakis C, Miyazawa K, Rodgers A, Talati J, Lotan Y. Epidemiology of stone disease across the world. World J Urol. 2017;35(9):1301-20. https://doi.org/10.1007/s00345-017-2008-6

3. Gadzhiev N, Prosyannikov M, Malkhasyan V, Akopyan G, Somani B, Sivkov A, Apolikhin O, Kaprin A. Urolithiasis prevalence in the Russian Federation: analysis of trends over a 15-year period. World J Urol. 202;39(10):3939-44. https://doi.org/10.1007/s00345-021-03729-y

4. Rule AD, Lieske JC, Li X, Melton LJ 3rd, Krambeck AE, Bergstralh EJ. The ROKS nomogram for predicting a second symptomatic stone episode. J Am Soc Nephrol. 2014;25(12):2878-86. https://doi.org/10.1681/ASN.2013091011

5. Turney BW, Reynard JM, Noble JG, Keoghane SR. Trends in urological stone disease. BJU Int. 2012;109(7):1082-7. https://doi.org/10.1111/j.1464-410X.2011.10495.x

6. Ferraro PM, Curhan GC, D'Addessi A, Gambaro G. Risk of recurrence of idiopathic calcium kidney stones: analysis of data from the literature. J Nephrol. 2017;30(2):227-33. https://doi.org/10.1007/s40620-016-0283-8

7. Wagner CA, Mohebbi N. Urinary pH and stone formation. J Nephrol. 2010;23 Suppl 16:S165-9. PMID: 21170875

8. Cicerello E. Uric acid nephrolithiasis: An update. Urologia. 2018;85(3):93-8. https://doi.org/10.1177/0391560318766823

9. Laube N, Berg W. Praxisorientiertes Kompendium. Uro-News. 2013;17(11):47-49. https://doi.org/10.1007/s00092-013-0411-x

10. Rennke HG, Denker BM. Renal Pathophysiology: The Essentials. 5th edition. Philadelphia: Wolters Kluwer; 2020. ISBN-10: 1975109597.

11. Murayama T, Taguchi H. The role of the diurnal variation of urinary pH in determining stone compositions. J Urol. 1993;150(5 Pt 1):1437-9. https://doi.org/10.1016/s0022-5347(17)35801-9

12. Simpson DP. Citrate excretion: a window on renal metabolism. Am J Physiol. 1983;244(3):F223-34. https://doi.org/10.1152/ajprenal.1983.244.3.F223

13. Kraut JA, Madias NE. Metabolic acidosis: pathophysiology, diagnosis and management. Nat Rev Nephrol. 2010;6(5):274-85. https://doi.org/10.1038/nrneph.2010.33

14. Strohmaier WL, Wrobel BM, Schubert G. Overweight, insulin resistance and blood pressure (parameters of the metabolic syndrome) in uric acid urolithiasis. Urol Res. 2012;40(2):171-5. https://doi.org/10.1007/s00240-011-0403-9

15. Maalouf NM, Cameron MA, Moe OW, Adams-Huet B, Sakhaee K. Low urine pH: a novel feature of the metabolic syndrome. Clin J Am Soc Nephrol. 2007;2(5):883-8. https://doi.org/10.2215/CJN.00670207

16. Spatola L, Ferraro PM, Gambaro G, Badalamenti S, Dauriz M. Metabolic syndrome and uric acid nephrolithiasis: insulin resistance in focus. Metabolism. 2018;83:225-33. https://doi.org/10.1016/j.metabol.2018.02.008

17. Gajiyev N.K., Malkhasyan V.A., Mazurenko D.V., Guseynov M.A., Tagirov N.S. Urolithiasis and metabolic syndrome. The pathophysiology of stone formation. Experimental and Clinical Urology. 2018;(1):66-75. (In Russ.) https://doi.org/10.29188/2222-8543-2018-9-1-66-75

18. Patschan D, Patschan S, Ritter O. Chronic Metabolic Acidosis in Chronic Kidney Disease. Kidney Blood Press Res. 2020;45(6):812-22. https://doi.org/10.1159/000510829

19. Bambach CP, Robertson WG, Peacock M, Hill GL. Effect of intestinal surgery on the risk of urinary stone formation. Gut. 1981;22(4):257-63. https://doi.org/10.1136/gut.22.4.257

20. Knudsen L, Marcussen H, Fleckenstein P, Pedersen EB, Jarnum S. Urolithiasis in chronic inflammatory bowel disease. Scand J Gastroenterol. 1978;13(4):433-6. https://doi.org/10.3109/00365527809181917

21. Lin PH, Ginty F, Appel LJ, Aickin M, Bohannon A, Garnero P, Barclay D, Svetkey LP. The DASH diet and sodium reduction improve markers of bone turnover and calcium metabolism in adults. J Nutr. 2003;133(10):3130-6. https://doi.org/10.1093/jn/133.10.3130

22. Meschi T, Maggiore U, Fiaccadori E, Schianchi T, Bosi S, Adorni G, Ridolo E, Guerra A, Allegri F, Novarini A, Borghi L. The effect of fruits and vegetables on urinary stone risk factors. Kidney Int. 2004;66(6):2402-10. https://doi.org/10.1111/j.1523-1755.2004.66029.x

23. Schwartz BF, Stoller ML. Nonsurgical management of infection-related renal calculi. Urol Clin North Am. 1999;26(4):765-78, viii. https://doi.org/10.1016/s0094-0143(05)70217-2

24. Parsons CL, Stauffer C, Mulholland SG, Griffith DP. Effect of ammonium on bacterial adherence to bladder transitional epithelium. J Urol. 1984;132(2):365-6. https://doi.org/10.1016/s0022-5347(17)49628-5

25. Jones BD, Mobley HL. Genetic and biochemical diversity of ureases of Proteus, Providencia, and Morganella species isolated from urinary tract infection. Infect Immun. 1987;55(9):2198-203. https://doi.org/10.1128/iai.55.9.2198-2203.1987

26. Flannigan R, Choy WH, Chew B, Lange D. Renal struvite stones--pathogenesis, microbiology, and management strategies. Nat Rev Urol. 2014;11(6):333-41. https://doi.org/10.1038/nrurol.2014.99

27. Dhayat NA, Gradwell MW, Pathare G, Anderegg M, Schneider L, Luethi D, Mattmann C, Moe OW, Vogt B, Fuster DG. Furosemide/Fludrocortisone Test and Clinical Parameters to Diagnose Incomplete Distal Renal Tubular Acidosis in Kidney Stone Formers. Clin J Am Soc Nephrol. 2017;12(9):1507-1517. https://doi.org/10.2215/CJN.01320217

28. Antonov V.G., Karpishchenko A.I. Acid-base state. In: Karpishchenko A.I., editor. Medical laboratory diagnostics: Programs and algorithms. 3rd edition, reprint and additional. Moscow: GEOTAR-Media; 2014. (In Russ.) ISBN: 978-5-9704-2958-7.

29. Welshman SG, McGeown MG. Urinary citrate excretion in stone-formers and normal controls. Br J Urol. 1976;48(1):7-11. https://doi.org/10.1111/j.1464-410x.1976.tb02731.x

30. Zuckerman JM, Assimos DG. Hypocitraturia: pathophysiology and medical management. Rev Urol. 2009;11(3):134-44. PMCID: PMC2777061

31. Fegan J, Khan R, Poindexter J, Pak CY. Gastrointestinal citrate absorption in nephrolithiasis. J Urol. 1992;147(5):1212-4. https://doi.org/10.1016/s0022-5347(17)37520-1

32. Unwin RJ, Capasso G, Shirley DG. An overview of divalent cation and citrate handling by the kidney. Nephron Physiol. 2004;98(2):p15-20. https://doi.org/10.1159/000080259

33. Zacchia M, Preisig P. Low urinary citrate: an overview. J Nephrol. 2010;23 Suppl 16:S49-56. PMID: 21170889

34. Hamm LL, Alpern RJ. Regulation of acid–base balance, citrate, and urine pH. In: Coe FL, Favus MJ, Pak CYC, Parks JH, Preminger GM, editors. Kidney Stones: Medical and Surgical Management. Lippincott-Raven; Philadelphia: 1996. ISBN-13: 978-0781702638.

35. Domrongkitchaiporn S, Stitchantrakul W, Kochakarn W. Causes of hypocitraturia in recurrent calcium stone formers: focusing on urinary potassium excretion. Am J Kidney Dis. 2006;48(4):546-54. https://doi.org/10.1053/j.ajkd.2006.06.008

36. Yang L, Wang K, Li H, Denstedt JD, Cadieux PA. The influence of urinary pH on antibiotic efficacy against bacterial uropathogens. Urology. 2014;84(3):731.e1-7. https://doi.org/10.1016/j.urology.2014.04.048

37. Ilyas R, Chow K, Young JG. What is the best method to evaluate urine pH? A trial of three urinary pH measurement methods in a stone clinic. J Endourol. 2015;29(1):70-4. https://doi.org/10.1089/end.2014.0317

38. Welch AA, Mulligan A, Bingham SA, Khaw KT. Urine pH is an indicator of dietary acid-base load, fruit and vegetables and meat intakes: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk population study. Br J Nutr. 2008;99(6):1335-43. https://doi.org/10.1017/S0007114507862350

39. Remer T, Manz F. Potential renal acid load of foods and its influence on urine pH. J Am Diet Assoc. 1995;95(7):791-7. https://doi.org/10.1016/S0002-8223(95)00219-7

40. Trinchieri A, Maletta A, Lizzano R, Marchesotti F. Potential renal acid load and the risk of renal stone formation in a case-control study. Eur J Clin Nutr. 2013;67(10):1077-80. https://doi.org/10.1038/ejcn.2013.155

41. Siener R, Hesse A. The effect of a vegetarian and different omnivorous diets on urinary risk factors for uric acid stone formation. Eur J Nutr. 2003;42(6):332-7. https://doi.org/10.1007/s00394-003-0428-0

42. Pinheiro VB, Baxmann AC, Tiselius HG, Heilberg IP. The effect of sodium bicarbonate upon urinary citrate excretion in calcium stone formers. Urology. 2013;82(1):33-7. https://doi.org/10.1016/j.urology.2013.03.002

43. Pearle MS, Goldfarb DS, Assimos DG, Curhan G, Denu-Ciocca CJ, Matlaga BR, Monga M, Penniston KL, Preminger GM, Turk TM, White JR; American Urological Assocation. Medical management of kidney stones: AUA guideline. J Urol. 2014;192(2):316-24. https://doi.org/10.1016/j.juro.2014.05.006

44. Rimer JD, Sakhaee K, Maalouf NM. Citrate therapy for calcium phosphate stones. Curr Opin Nephrol Hypertens. 2019;28(2):130-139. https://doi.org/10.1097/MNH.0000000000000474

45. Barcelo P, Wuhl O, Servitge E, Rousaud A, Pak CY. Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol. 1993;150(6):1761-4. https://doi.org/10.1016/s0022-5347(17)35888-3

46. Dauw CA, Yi Y, Bierlein MJ, Yan P, Alruwaily AF, Ghani KR, Wolf JS Jr, Hollenbeck BK, Hollingsworth JM. Factors Associated With Preventive Pharmacological Therapy Adherence Among Patients With Kidney Stones. Urology. 2016;93:45-9. https://doi.org/10.1016/j.urology.2016.03.030

47. Shamash J, Earl H, Souhami R. Acetazolamide for alkalinisation of urine in patients receiving high-dose methotrexate. Cancer Chemother Pharmacol. 1991;28(2):150-1. https://doi.org/10.1007/BF00689708

48. Sterrett SP, Penniston KL, Wolf JS Jr, Nakada SY. Acetazolamide is an effective adjunct for urinary alkalization in patients with uric acid and cystine stone formation recalcitrant to potassium citrate. Urology. 2008;72(2):278-81. https://doi.org/10.1016/j.urology.2008.04.003

49. Van Berkel MA, Elefritz JL. Evaluating off-label uses of acetazolamide. Am J Health Syst Pharm. 2018;75(8):524-531. https://doi.org/10.2146/ajhp170279

50. Jarrar K, Boedeker RH, Weidner W. Struvite stones: long term follow up under metaphylaxis. Ann Urol (Paris). 1996;30(3):112-7. PMID: 8766146

51. Bibby JM, Hukins DW. Acidification of urine is not a feasible method for preventing encrustation of indwelling urinary catheters. Scand J Urol Nephrol. 1993;27(1):63-5. https://doi.org/10.3109/00365599309180415

52. Wall I, Tiselius HG. Long-term acidification of urine in patients treated for infected renal stones. Urol Int. 1990;45(6):336-41. https://doi.org/10.1159/000281732

53. Siener R, Struwe F, Hesse A. Effect of L-Methionine on the Risk of Phosphate Stone Formation. Urology. 2016;98:39-43. https://doi.org/10.1016/j.urology.2016.08.007

54. Karki N, Leslie SW. Struvite And Triple Phosphate Renal Calculi. 2022 May 27. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Bookshelf ID: NBK568783

55. Barton CH, Sterling ML, Thomas R, Vaziri ND, Byrne C, Ryan G. Ineffectiveness of intravenous ascorbic acid as an acidifying agent in man. Arch Intern Med. 1981;141(2):211-2. PMID: 7458517

56. Hetey SK, Kleinberg ML, Parker WD, Johnson EW. Effect of ascorbic acid on urine pH in patients with injured spinal cords. Am J Hosp Pharm. 1980 Feb;37(2):235-7. PMID: 7361797

57. Skolarikos A, Neisius A, Petřík A, Somani B, Thomas K, Gambaro G. Urolithiasis. In: EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam, 2022. ISBN 978-94-92671-16-5. URL: https://uroweb.org/guideline/urolithiasis/